Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database

Abstract The combination of immune checkpoint inhibitors (ICIs), such as ipilimumab and nivolumab, has revolutionized cancer treatment, particularly for advanced melanoma and other solid tumors. However, rare adverse events (AEs) associated with this combination are often underreported in clinical t...

Full description

Saved in:
Bibliographic Details
Main Authors: Xianyu Dai, Hongliang Cao, Jiajun Li, Tao Zhang, Yuchuan Hou
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-07287-w
Tags: Add Tag
No Tags, Be the first to tag this record!